Ono Pharmaceutical Co Stock Gross Profit
| OPHLY Stock | USD 3.59 0.09 2.45% |
Ono Pharmaceutical Co fundamentals help investors to digest information that contributes to Ono Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Ono Pink Sheet. The fundamental analysis module provides a way to measure Ono Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ono Pharmaceutical pink sheet.
Ono |
Ono Pharmaceutical Co Company Gross Profit Analysis
Ono Pharmaceutical's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Ono Pharmaceutical Gross Profit | 267.85 B |
Most of Ono Pharmaceutical's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ono Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Ono Pharmaceutical Co reported 267.85 B of gross profit. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The gross profit for all United States stocks is significantly lower than that of the firm.
Ono Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ono Pharmaceutical's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ono Pharmaceutical could also be used in its relative valuation, which is a method of valuing Ono Pharmaceutical by comparing valuation metrics of similar companies.Ono Pharmaceutical is currently under evaluation in gross profit category among its peers.
Ono Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 1.47 B | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 18.66 X | |||
| Price To Book | 2.34 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 361.36 B | |||
| Gross Profit | 267.85 B | |||
| EBITDA | 123.45 B | |||
| Net Income | 80.52 B | |||
| Cash And Equivalents | 136.18 B | |||
| Cash Per Share | 92.88 X | |||
| Total Debt | 8.65 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | 491.93 X | |||
| Cash Flow From Operations | 61.83 B | |||
| Earnings Per Share | 0.58 X | |||
| Number Of Employees | 3.69 K | |||
| Beta | 0.26 | |||
| Market Capitalization | 10.55 B | |||
| Total Asset | 739.2 B | |||
| Retained Earnings | 466.64 B | |||
| Working Capital | 163.56 B | |||
| Current Asset | 218.78 B | |||
| Current Liabilities | 55.22 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.82 % | |||
| Net Asset | 739.2 B | |||
| Last Dividend Paid | 28.0 |
About Ono Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ono Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ono Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ono Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ono Pink Sheet Analysis
When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.